Compare AbbVie Inc (ABBV) vs Realty Income Corp (O) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Realty Income Corp — how do they compare? AbbVie Inc trades at $252.62 (market cap $449.91B), while Realty Income Corp trades at $63.25 (market cap $59.69B). The key difference: AbbVie Inc is far larger — about 7.5× Realty Income Corp's market cap, and Realty Income Corp pays the higher dividend (5.08%). Which is the better fit depends on your goals.
| ABBV | O | |
|---|---|---|
Market Cap | $449.91B | $59.69B |
Sector | Health | Real Estate |
52-Week High | $261.07 | $67.56 |
52-Week Low | $184.85 | $55.93 |
Enterprise Value | $513.38B | $89.49B |
Dividend Yield | 2.72% | 5.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
Realty Income (O) trades at $64.01, up 0.27% with a bullish technical signal from moving averages. The REIT maintains strong fundamentals with $5.75B revenue (2025), 92.54% gross margins, and consistent monthly dividends. Recent earnings missed expectations for three consecutive quarters, but analyst consensus remains positive with a $67.86 price target. Operating cash flow grew to $4.0B in 2025, though debt-to-asset ratio increased to 39.93%.
Outlook remains stable with dividend reliability as a key strength, but elevated P/E (51.8) and recent earnings misses pose valuation concerns. Risks include rising leverage and interest rate sensitivity. Institutional sentiment leans bullish (41% buy ratings), supporting moderate upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →
